Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

ChinaBio® Partnering Forum Draws 558 Attendees

publication date: Jul 1, 2010
 | 
author/source: Richard Daverman, PhD
SUZHOU, China--The Second Annual ChinaBio® Partnering Forum 2010, held June 23-24 in Suzhou, China, generated a very successful round of meetings, according to co-organizers ChinaBio® LLC and EBD Group. This year’s Partnering Forum was host to 337 companies from 23 countries. At least 654 one-to-one meetings were held between the 558 attendees.

The event was hosted by BioBay life science park, said to be the fastest growing life science park in China. BioBay also provided the venue: the Cold Spring Harbor Asia Conference Center, located next to BioBay in Suzhou Industrial Park.

ChinaBio® Partnering Forum was created to bring early-stage China companies seeking partnerships together with more well-established pharma and biotech companies from Europe, the U.S. and elsewhere. The event was attended by representatives from life science companies, venture capital, academia and service organizations from China and around the world that were seeking new technologies or co-development opportunities.

“With over 200 attendees from outside China, the ChinaBio® Partnering Forum is now one of the most international conferences focused on life science in China,” explained Greg Scott, CEO and founder of ChinaBio® LLC. “Our second Partnering Forum in China built upon the success of the first, bringing more people from a wider variety of countries and companies.”

“We were very pleased by the high level of participation in the conference,” added Carola Schropp, CEO and founder of EBD Group. “With over 2,000 meeting requests resulting in 654 one-to-one meetings, it’s apparent that our Chinese participants are quickly learning to take advantage of our partneringONE® system.”

Partnering has become a significant component of China’s explosive biopharma industry. The number of partnering deals grew by 41% in 2009, with co-development deals the fastest growing segment, according to data from ChinaBio Consulting. The rapid increase has been driven by China’s robust pipeline of over 2,000 novel molecules, nearly 200 of which are in clinical development.

A total of 36 biotech companies and entrepreneurs presented their products, technologies and corporate strategies. Big pharma, along with other companies seeking technologies and partners, discussed their areas of research and product development.

The Third Annual ChinaBio® Partnering Forum, already in planning, will be held in Beijing next year. More information about both this year’s and next year’s events are available at www.ebdgroup.com/cbpf.

 

Share this with colleagues:

 

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital